Form 4: Polaris Partners' Amir Nashat Reports Camp4 Therapeutics Corp Holdings After IPO

Amir Nashat, a director and affiliated with Polaris Partners, reports changes in beneficial ownership of Camp4 Therapeutics Corp stock following the company's initial public offering.

Summary

• Amir Nashat, a director of Camp4 Therapeutics Corp and affiliated with Polaris Partners, filed a Form 4 detailing changes in beneficial ownership.
• The filing reflects transactions occurring on October 15, 2024, coinciding with the closing of Camp4 Therapeutics' initial public offering (IPO).
• Series A Prime Convertible Preferred Stock and Series B Preferred Stock automatically converted into Common Stock at a rate of 11.2158-for-one.
• Nashat reports indirect ownership through Polaris Partners VII, L.P. (PP VII), Polaris Entrepreneurs' Fund VII, L.P. (PEF VII), and Polaris Partners X, L.P. (PP X).
• Polaris Partners X, L.P. purchased 909,090 shares of common stock at $11 per share.
• Nashat disclaims beneficial ownership of the securities except to the extent of his pecuniary interests.

Sentiment

Score: 7

Explanation: The document reflects standard post-IPO transactions and insider ownership reporting. Polaris Partners' continued investment is a positive signal, but the document itself is neutral in tone.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure following the IPO.
• Polaris Partners' continued investment in Camp4 Therapeutics, as evidenced by the purchase of 909,090 shares, signals confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements about Camp4 Therapeutics' future performance, but the conversion of preferred stock and purchase of common stock suggest ongoing investment and participation by Polaris Partners.

Industry Context

Form 4 filings are standard practice after significant events like IPOs, providing transparency into the ownership structure and insider transactions of publicly traded companies. This filing indicates the conversion of preferred shares held by venture capital firms into common stock, which is a typical step following an IPO.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for company insiders and major shareholders, such as Amir Nashat and Polaris Partners, to report changes in their beneficial ownership of company stock.
• The conversion of preferred stock to common stock upon an IPO is a common practice in the venture capital and biotech industries, as it simplifies the company's capital structure and aligns the interests of early investors with those of public shareholders.
• The size of Polaris Partners' stake in Camp4 Therapeutics is typical for venture capital firms that have invested in a company from its early stages.

Stakeholder Impact

• The conversion of preferred stock to common stock may be viewed positively by shareholders as it simplifies the capital structure.
• Polaris Partners' continued investment could instill confidence in the company's prospects.

Key Dates